Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 18Uveal Melanoma 4Prostatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Sarcoma 2Salivary Gland Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Intraocular Lymphoma 2Hodgkin Disease 2Brain Neoplasms 2Anus Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1

Interventions

pembrolizumab 8Nivolumab 5avelumab 4Ipilimumab 4Radiotherapy 2Radiosurgery 2ALT-803 2tremelimumab 1talimogene laherparepvec 1sapanisertib 1prednylidene 1poly ICLC 1lenvatinib 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1deltacortene 1cemiplimab 1cabozantinib 1bempegaldesleukin 1atezolizumab 1Tacrolimus 1Radiation Dose Hypofractionation 1Radiation 1Prednisone 1Interferon-gamma 1Interferon-beta 1CTLA-4 Antigen 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Merkel Cell × CTLA-4 Antigen × Clear all
NCT03816332 2026-04-30

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
12 enrolled 13 charts
Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡